Environmental enteric dysfunction in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 63, Issue 1, 2016, Pages 6-14

  Syed, Sana ^a   Ali, Asad ^b   Duggan, Christopher ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

diarrheal diseases; environmental enteric dysfunction; interventions; malnutrition

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBODY; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CALGRANULIN; CORTICOSTEROID; LACTOFERRIN; LARAZOTIDE; MESALAZINE; MONGERSEN; MYELOPEROXIDASE; ORAL POLIOMYELITIS VACCINE; PROBIOTIC AGENT; ROTAVIRUS VACCINE; WATER;

BACTERIAL TRANSLOCATION; CELL FUNCTION; CHILD DEATH; CHRONIC INFLAMMATION; CLINICAL FEATURE; ENTERITIS; ENVIRONMENTAL ENTERIC DYSFUNCTION; HISTOPATHOLOGY; HUMAN; HYGIENE; IMMUNOSTIMULATION; INCIDENCE; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE INFECTION; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; MALABSORPTION; MALNUTRITION; MICROBIOME; NUTRITIONAL SUPPORT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SANITATION; SMALL INTESTINE DISEASE; STUNTING; TISSUE REGENERATION; CHILD HEALTH; ENTEROPATHY; ENVIRONMENTAL EXPOSURE; FEMALE; GLOBAL HEALTH; INFANT; INFANTILE DIARRHEA; MALE; MICROBIOLOGY; NEWBORN; POVERTY; PRESCHOOL CHILD;

CHILD HEALTH; CHILD, PRESCHOOL; DIARRHEA, INFANTILE; ENVIRONMENTAL EXPOSURE; FEMALE; GLOBAL HEALTH; HUMANS; HYGIENE; INFANT; INFANT, NEWBORN; INTESTINAL DISEASES; MALE; POVERTY;

EID: 84961221507     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001147     Document Type: Review

References (102)

1. WHO. Diarrhoeal disease 2013 [08/24/2015]. http://www.who.int/mediacentre/factsheets/fs330/en. Accessed August 24, 2015.
2. Adair LS, Fall CH, Osmond C, et al. Associations of linear growth and relative weight gain during early life with adult health and human capital in countries of low and middle income: findings from five birth cohort studies. Lancet 2013; 382: 525-34.
3. Victora CG, De Onis M, Hallal PC, et al. Worldwide timing of growth faltering: revisiting implications for interventions. Pediatrics 2010; 125: e473-80.
4. Bhutta ZA, Ahmed T, Black RE, et al. What works?. Interventions for maternal and child undernutrition and survival. Lancet 2008; 371: 417-40.
5. Snyder JD, Merson MH. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull World Health Organ 1982; 60: 605-13.
6. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151-61.
7. Stevens GA, Finucane MM, Paciorek CJ, et al. Trends in mild, moderate, and severe stunting and underweight, and progress towards MDG 1 in 141 developing countries: a systematic analysis of population representative data. Lancet 2012; 380: 824-34.
8. Marriott BP, White A, Hadden L, et al. World Health Organization (WHO) infant and young child feeding indicators: associations with growth measures in 14 low-income countries. Matern Child Nutr 2012; 8: 354-70.
9. Krebs NF, Mazariegos M, Chomba E, et al. Randomized controlled trial of meat compared with multimicronutrient-fortified cereal in infants and toddlers with high stunting rates in diverse settings. Am J Clin Nutr 2012; 96: 840-7.
10. Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009; 374: 1032-5.
11. Keusch GT, Denno DM, Black RE, et al. Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. Clin Infect Dis 2014; 59(suppl 4): S207-12.
12. Keusch GT, Rosenberg IH, Denno DM, et al. Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low- and middle-income countries. Food Nutr Bull 2013; 34: 357-64.
13. Korpe PS, Petri WAJr. Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med 2012; 18: 328-36.
14. Prendergast A, Kelly P. Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg 2012; 86: 756-63.
15. Chacko CJ, Paulson KA, Mathan VI, et al. The villus architecture of the small intestine in the tropics: a necropsy study. J Pathol 1969; 98: 146-51.
16. Lindenbaum J, Gerson CD, Kent TH. Recovery of small-intestinal structure and function after residence in the tropics. I. Studies in Peace Corps volunteers. Ann Intern Med 1971; 74: 218-22.
17. Keusch GT. Subclinical malabsorption in Thailand. I. Intestinal absorption in Thai children. Am J Clin Nutr 1972; 25: 1062-6.
18. Galpin L, Manary MJ, Fleming K, et al. Effect of Lactobacillus GG on intestinal integrity in Malawian children at risk of tropical enteropathy. Am J Clin Nutr 2005; 82: 1040-5.
19. Thurnham DI, Northrop-Clewes CA, McCullough FS, et al. Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants. J Infect Dis 2000; 182(suppl 1): S23-8.
20. Goto R, Panter-Brick C, Northrop-Clewes CA, et al. Poor intestinal permeability in mildly stunted Nepali children: associations with weaning practices and Giardia lamblia infection. Br J Nutr 2002; 88: 141-9.
21. Fagundes Neto U, Martins MC, Lima FL, et al. Asymptomatic environmental enteropathy among slum-dwelling infants. J Am Coll Nutr 1994; 13: 51-6.
22. Qadri F, Bhuiyan TR, Sack DA, et al. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 2013; 31: 452-60.
23. Lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability, mucosal injury, and growth faltering in Gambian infants. Lancet 1991; 338: 907-10.
24. Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. J Nutr 2003; 133: 1332-8.
25. Solomons NW. Environmental contamination and chronic inflammation influence human growth potential. J Nutr 2003; 133: 1237.
26. Campbell DI, Murch SH, Elia M, et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function. Pediatr Res 2003; 54: 306-11.
27. Brown EM, Wlodarska M, Willing BP, et al. Diet and specific microbial exposure trigger features of environmental enteropathy in a novel murine model. Nat Commun 2015; 6: 7806.
28. Campbell DI, McPhail G, Lunn PG, et al. Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, Giardia lamblia, and intestinal permeability. J Pediatr Gastroenterol Nutr 2004; 39: 153-7.
29. Trehan I, Shulman RJ, Ou CN, et al. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. Am J Gastroenterol 2009; 104: 2326-2333.
30. Nath SK. Tropical sprue. Curr Gastroenterol Rep 2005; 7: 343-9.
31. Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40: 1-19.
32. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
33. Krawinkel MB, Scholz D, Busch A, et al. Chronic intestinal failure in children. Deutsches Arzteblatt Int 2012; 109: 409-15.
34. Peterson KM, Buss J, Easley R, et al. REG1B as a predictor of childhood stunting in Bangladesh and Peru. Am J Clin Nutr 2013; 97: 1129-33.
35. Shiner M. Coeliac disease: histopathological findings in the small intestinal mucosa studies by a peroral biopsy technique. Gut 1960; 1: 48-54.
36. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566-81.
37. Ford RP, Menzies IS, Phillips AD, et al. Intestinal sugar permeability: relationship to diarrhoeal disease and small bowel morphology. J Pediatr Gastroenterol Nutr 1985; 4: 568-74.
38. Nathavitharana KA, Lloyd DR, Raafat F, et al. Urinary mannitol: lactulose excretion ratios and jejunal mucosal structure. Arch Dis Child 1988; 63: 1054-9.
39. Lee GO, Kosek P, Lima AA, et al. Lactulose: mannitol diagnostic test by HPLC and LC-MSMS platforms: considerations for field studies of intestinal barrier function and environmental enteropathy. J Pediatr Gastroenterol Nutr 2014; 59: 544-50.
40. Weisz AJ, Manary MJ, Stephenson K, et al. Abnormal gut integrity is associated with reduced linear growth in rural Malawian children. J Pediatr Gastroenterol Nutr 2012; 55: 747-50.
41. Crossley JR, Elliott RB. Simple method for diagnosing protein-losing enteropathies. Br Med J 1977; 1: 428-9.
42. Kosek M, Haque R, Lima A, et al. Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. Am J Trop Med Hyg 2013; 88: 390-6.
43. Peters JH, Wierdsma NJ, Teerlink T, et al. The citrulline generation test: proposal for a new enterocyte function test. Aliment Pharmacol Ther 2008; 27: 1300-10.
44. Crenn P, Vahedi K, Lavergne-Slove A, et al. Plasma citrulline: a marker of enterocyte mass in villous atrophy-Associated small bowel disease. Gastroenterology 2003; 124: 1210-9.
45. Papadia C, Sherwood RA, Kalantzis C, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol 2007; 102: 1474-82.
46. Gosselin KB, Feldman HA, Sonis AL, et al. Serum citrulline as a biomarker of gastrointestinal function during hematopoietic cell transplantation in children. J Pediatr Gastroenterol Nutr 2014; 58: 709-14.
47. Lutgens LC, Deutz N, Granzier-Peeters M, et al. Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol, Biol, Phys 2004; 60: 275-85.
48. McDonald C, Hao T, Gosselin K, et al. Elevations in serum antiflagellin and anti-lipopolysaccharide immunoglobulins are related to underweight in young Tamzanian children. FASEB J 2015; 29(suppl 403.4).
49. Piton G, Manzon C, Cypriani B, et al. Acute intestinal failure in critically ill patients: is plasma citrulline the right marker?. Intensive Care Med 2011; 37: 911-7.
50. Cannon JG. Inflammatory cytokines in nonpathological states. News Physiol Sci 2000; 15: 298-303.
51. Siebert S, Tsoukas A, Robertson J, et al. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 2015; 67: 280-309.
52. Jiang NM, Tofail F, Moonah SN, et al. Febrile illness and proinflammatory cytokines are associated with lower neurodevelopmental scores in Bangladeshi infants living in poverty. BMC Pediatr 2014; 14: 50.
53. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-Analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894-9.
54. Kapel N, Campeotto F, Kalach N, et al. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr 2010; 51: 542-7.
55. Dorosko SM, Mackenzie T, Connor RI. Fecal calprotectin concentrations are higher in exclusively breastfed infants compared to those who are mixed-fed. Breastfeed Med 2008; 3: 117-9.
56. Williams JG, Hughes LE, Hallett MB. Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease. Gut 1990; 31: 187-93.
57. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344-50.
58. Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med 1980; 303: 27-34.
59. Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 1992; 30: 1238-42.
60. Steiner TS, Flores CA, Pizarro TT, et al. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 1997; 4: 719-22.
61. Alcantara CS, Yang CH, Steiner TS, et al. Interleukin-8, tumor necrosis factor-Alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. Am J Trop Med Hyg 2003; 68: 325-8.
62. Murr C, Widner B, Wirleitner B, et al. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-87.
63. Ziegler TR, Luo M, Estivariz CF, et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2008; 294: R402-10.
64. Galloway DP, Troutt ML, Kocoshis SA, et al. Increased anti-flagellin and anti-lipopolysaccharide immunoglobulins in pediatric intestinal failure: associations with fever and central line-Associated bloodstream infections. JPEN J Parenter Enteral Nutr 2015; 39: 562-8.
65. Miyaoka Y, Kadowaki Y, Ishihara S, et al. Transgenic overexpression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages. Oncogene 2004; 23: 3572-9.
66. Kawanami C, Fukui H, Kinoshita Y, et al. Regenerating gene expression in normal gastric mucosa and indomethacin-induced mucosal lesions of the rat. J Gastroenterol 1997; 32: 12-8.
67. Watanabe T, Yonekura H, Terazono K, et al. Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. J Biol Chem 1990; 265: 7432-9.
68. Peterson KM, Guo X, Elkahloun AG, et al. The expression of REG 1A and REG 1B is increased during acute amebic colitis. Parasitol Int 2011; 60: 296-300.
69. Dieckgraefe BK, Crimmins DL, Landt V, et al. Expression of the regenerating gene family in inflammatory bowel disease mucosa: Reg Ialpha upregulation, processing, and antiapoptotic activity. J Investig Med 2002; 50: 421-34.
70. Sekikawa A, Fukui H, Fujii S, et al. Possible role of REG Ialpha protein in ulcerative colitis and colitic cancer. Gut 2005; 54: 1437-44.
71. Petri WA, Naylor C, Haque R. Environmental enteropathy and malnutrition: do we know enough to intervene?. BMC Med 2014; 12: 187.
72. Chen P, Soares AM, Lima AA, et al. Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort data from northeastern Brazil. J Health, Popul Nutr 2003; 21: 309-15.
73. Williams EA, Elia M, Lunn PG. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering Gambian infants. Am J Clin Nutr 2007; 86: 421-7.
74. Lima NL, Soares AM, Mota RM, et al. Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula. J Pediatr Gastroenterol Nutr 2007; 44: 365-74.
75. Lima AA, Brito LF, Ribeiro HB, et al. Intestinal barrier function and weight gain in malnourished children taking glutamine supplemented enteral formula. J Pediatr Gastroenterol Nutr 2005; 40: 28-35.
76. Smith HE, Ryan KN, Stephenson KB, et al. Multiple micronutrient supplementation transiently ameliorates environmental enteropathy in Malawian children aged 12-35 months in a randomized controlled clinical trial. J Nutr 2014; 144: 2059-65.
77. Jones KD, Hunten-Kirsch B, Laving AM, et al. Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial. BMC Med 2014; 12: 133.
78. Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 2015; 148: 1311-9e6.
79. Lahad A, Weiss B Current therapy of pediatric Crohn?s disease.World J Gastrointest Pathophysiol 2015; 6: 33-42
80. Regan BP, Bousvaros A. Pediatric ulcerative colitis: a practical guide to management. Paediatr Drugs 2014; 16: 189-98.
81. Perrotta C, Pellegrino P, Moroni E, et al. Five-Aminosalicylic acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract 2015; 2015: 456895.
82. Scott FI, Osterman MT. Medical management of Crohn disease. Clin Colon Rectal Surg 2013; 26: 67-74.
83. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn?s disease. N Engl J Med 2015; 372: 1104-13.
84. Kosek M, Guerrant RL, Kang G, et al. Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework. Clin Infect Dis 2014; 59(suppl 4): S239-47.
85. George CM, Oldja L, Biswas S, et al. Geophagy is associated with environmental enteropathy and stunting in children in rural Bangladesh. Am J Trop Med Hyg 2015; 92: 1117-24.
86. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 2015; 3: e564-75.
87. Group NHW, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome Res 2009; 19: 2317-23.
88. Gough EK, Stephens DA, Moodie EE, et al. Linear growth faltering in infants is associated with Acidaminococcus sp. and community-level changes in the gut microbiota. Microbiome 2015; 3: 24.
89. Subramanian S, Huq S, Yatsunenko T, et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature 2014; 510: 417-21.
90. Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013; 339: 548-54.
91. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-7.
92. Horton R. Maternal and child undernutrition: an urgent opportunity. Lancet 2008; 371: 179.
93. Huda MN, Lewis Z, Kalanetra KM, et al. Stool microbiota and vaccine responses of infants. Pediatrics 2014; 134: e362-72.
94. Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014; 158: 705-21.
95. The PROVIDE Study (Performance of Rotavirus and Oral Polio Vaccines in Developing Countries) [November 17, 2015]. https://www.providestudy.org. Accessed August 24, 2015.
96. Kirkpatrick BD, Colgate ER, Mychaleckyj JC, et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. Am J Trop Med Hyg 2015; 92: 744-51.
97. Arnold BF, Null C, Luby SP, et al. Cluster-randomised controlled trials of individual and combined water, sanitation, hygiene and nutritional interventions in rural Bangladesh and Kenya: the WASH Benefits study design and rationale. BMJ Open 2013; 3: e003476.
98. Bartram J, Cairncross S. Hygiene, sanitation, and water: forgotten foundations of health. PLoS Med 2010; 7: e1000367.
99. Luby S. Is targeting access to sanitation enough?. Lancet Glob Health 2014; 2: E619-20.
100. Clasen T, Boisson S, Routray P, et al. Effectiveness of a rural sanitation programme on diarrhoea, soil-transmitted helminth infection, and child malnutrition in Odisha, India: a cluster-randomised trial. Lancet Glob Health 2014; 2: e645-53.
101. Brown J, Cumming O, Bartram J, et al. A controlled, before-And-After trial of an urban sanitation intervention to reduce enteric infections in children: research protocol for the Maputo Sanitation (MapSan) study, Mozambique. BMJ Open 2015; 5: e008215.
102. Mbuya MN, Tavengwa NV, Stoltzfus RJ, et al. Design of an intervention to minimize ingestion of fecal microbes by young children in rural Zimbabwe. Clin Infect Dis 2015; 61(suppl 7): S703-9.